Enteroglucagon
Enteroglucagon is a
It consists of 37 amino acids. Enteroglucagon is released when fats and glucose are present in the small intestine; which decrease the motility to allow sufficient time for these nutrients to be absorbed.Discovery
In 1948, Sutherland and De Duve identified a gastrointestinal glucagon-like material in gastric mucosa,[2] the term "enteroglucagon" was used to describe this material that shared a similar immunoreactivity with glucagon.[3] A half-century later, Brubaker and Drucker[4] studied proglucagon gene expression, they discovered the function of enteroglucagon is related to the growth of intestinal epithelium.[5]
Function
Enteroglucagon is a proglucagon-derived peptide or enteroendocrine cells derived peptide in the small intestine. Preproglucagon undergoes
Clinical significance
GLP-1 is effective at reducing blood glucose levels. GLP-1 analogs have a significant therapeutic effect and high efficacy on diabetes treatments and hypoglycemia prevention.[8] Proliferation effect and trophic effect on the small intestine, GLP-2 is used as a therapy to support patients with short-bowel syndrome and other underlying intestinal conditions.[9]
See also
References
External links
- Overview at colostate.edu
- Nosek, Thomas M. "Section 6/6ch2/s6ch2_27". Essentials of Human Physiology. Archived from the original on 2016-03-24.
- Enteroglucagon at the U.S. National Library of Medicine Medical Subject Headings (MeSH)